Zhittya Genesis Medicine continues to cooperate and work with research and laboratory staff at the University of Nevada, Reno where Zhittya conducts some of its research related to FGF-1, Parkinson’s Disease, and more.

Zhittya Genesis Medicine’s partner in patient facilitation, patient logistics, and operations based in Los Angeles, California. Cross Border Medical Tourism ensures that all of our patients are cared for throughout our programs.

Zhittya Genesis Medicine’s marketing partner based in Las Vegas, Nevada, helping Zhittya Genesis Medicine market and distribute our potential treatment following anticipated approval by the US FDA and other regulatory bodies.

Zhittya Genesis Medicine’s January 2024 update provides an insightful overview of their ongoing efforts and groundbreaking research in 2024. The company is making strides in treating Parkinson's disease especially as they work to develop strategic collaborations with renowned medical imaging centers in the United States and Italy. These partnerships aim to scientifically demonstrate how FGF-1 enhances brain blood flow and potentially reverses disease symptoms.

Zhittya Genesis Medicine’s February 2024 update details the company's busy start to the year, with significant developments in their research and treatment offerings, particularly focusing on FGF-1's potential in addressing various diseases. Zhittya recounts successful presentations and interactions at the Dubai Cardiovascular Conference, emphasizing the international medical community's growing interest in FGF-1 for treating small vessel heart disease, Parkinson’s disease, and other neurodegenerative conditions. Additionally, it highlights the progress in brain scanning and blood flow imaging studies, aiming to empirically demonstrate FGF-1's effectiveness in improving cerebral blood perfusion.

February 2024:

Zhittya Genesis Medicine completes the production of additional FGF-1 with its partners. This new batch of FGF-1 will allow for Zhittya Genesis Medicine to continue to conduct studies into the future for Parkinson’s Disease.

Zhittya Genesis Medicine’s March 2024 update discusses their recent activities, particularly focusing on the treatment of Parkinson's disease patients with FGF-1 through their ongoing medical research studies. The company's ongoing research is exploring how continual dosing with FGF-1 can aid in the recovery and improvement of patients' conditions. Despite the uncertainties and the complex journey of discovery, positive changes in patients have been observed, leading to renewed hope and potential treatment strategies. Additionally, the update delves into the intriguing aspect of where the administered FGF-1 goes within the brain, considering the vast number of molecules unaccounted for and the possible extensive repair work being undertaken within the brain's complex structure.

April 2024:

Zhittya Genesis Medicine is proud to announce that they have dosed their 150th Parkinson’s Disease patient in their medical research studies, proving as a substantial milestone for Zhittya’s potential treatment. With 150 patients now dosed, Zhittya has seen no reported adverse events and a 53% improvement, on average, in reported motor scores.

This update from Zhittya Genesis Medicine, dated April 2024, highlights their continued efforts in advancing treatments for Parkinson’s disease and other health conditions using FGF-1. The company celebrates treating over 150 Parkinson's disease sufferers with notable improvements and minimal side effects. As the two-year mark approaches since the first human dosing, they are beginning to gather long-term efficacy data. Furthermore, the update contrasts FGF-1 treatment with deep brain stimulation (DBS), emphasizing FGF-1's non-invasive application and broader health benefits over the surgical and potentially riskier DBS.

Zhittya Genesis Medicine’s latest update provides an insightful overview of their ongoing efforts and groundbreaking research in 2024. The company has achieved significant milestones, including the first brain scan measuring blood perfusion in a Parkinson’s patient and a successful spinal tap delivery of FGF-1. Their recent conference in The Bahamas highlighted potential treatments for Parkinson’s and coronary heart disease, and they are planning new applications for critical leg ischemia and diabetic foot ulcers. Celebrating two years of treating Parkinson's patients, Zhittya has treated over 150 subjects and continues to work with US agencies to seek approval for their innovative treatments.

May 2024:

Zhittya Genesis Medicine celebrates its second year of conducting Parkinson’s Disease medical research studies, which has treated over 150 individuals suffering from Parkinson’s Disease.

Zhittya Genesis Medicine's June 2024 update highlights their significant advancements in medical research. The company has received regulatory clearance to begin studies for severe heart disease in The Bahamas, Parkinson's disease in The Bahamas, and critical limb ischemia in the British Virgin Islands. Their recent trip to the British Virgin Islands marked the dosing of their 175th Parkinson’s patient with FGF-1, showing promising results. Upcoming initiatives include presentations in Armenia and a strong presence at FreedomFest in Las Vegas. Zhittya is also seeking pre-IPO investment to fund these expanding operations and research efforts. CEO Dan Montano underscores the urgency of advancing treatments, particularly for heart disease, the leading cause of death globally.

Zhittya Genesis Medicine has obtained regulatory clearance to begin conducting research studies in The Bahamas. Zhittya Genesis Medicine will begin utilizing FGF-1 in patients suffering from Parkinson’s disease utilizing an intranasal delivery method. Zhittya plan to begin these studies in the coming months.

Zhittya Genesis Medicine's June 2024 update highlights their significant advancements in medical research. The company has received regulatory clearance to begin studies for severe heart disease in The Bahamas, Parkinson's disease in The Bahamas, and critical limb ischemia in the British Virgin Islands. Their recent trip to the British Virgin Islands marked the dosing of their 175th Parkinson’s patient with FGF-1, showing promising results. Upcoming initiatives include presentations in Armenia and a strong presence at FreedomFest in Las Vegas. Zhittya is also seeking pre-IPO investment to fund these expanding operations and research efforts. CEO Dan Montano underscores the urgency of advancing treatments, particularly for heart disease, the leading cause of death globally.

Zhittya Genesis Medicine's August 2024 update outlines their continued progress in treating Parkinson's disease and severe heart disease. In the British Virgin Islands, Cohort #27 for Parkinson's treatment began, with the company having now treated 180 patients with no significant adverse events. The update highlights improved motor and mental skills in patients and discusses plans to refine dosing protocols for better outcomes. Zhittya also made advancements in heart disease treatment, obtaining clearance in The Bahamas and receiving an overwhelming response from patients. Additionally, Dr. Jacobs is scheduled to present in Kuwait on Parkinson's treatments in October, further expanding Zhittya’s global presence. The company continues to seek pre-IPO investment to support these initiatives.

Zhittya Genesis Medicine's August 2024 update outlines their continued progress in treating Parkinson's disease and severe heart disease. In the British Virgin Islands, Cohort #27 for Parkinson's treatment began, with the company having now treated 180 patients with no significant adverse events. The update highlights improved motor and mental skills in patients and discusses plans to refine dosing protocols for better outcomes. Zhittya also made advancements in heart disease treatment, obtaining clearance in The Bahamas and receiving an overwhelming response from patients. Additionally, Dr. Jacobs is scheduled to present in Kuwait on Parkinson's treatments in October, further expanding Zhittya’s global presence. The company continues to seek pre-IPO investment to support these initiatives.

Zhittya Genesis Medicine's October 2024 update highlights continued progress in treating neurodegenerative diseases. A notable case is shared involving a patient who, despite a severe stroke three days prior to treatment, experienced significant recovery over nine months, regaining mobility and cognitive abilities. CEO Dan Montano reflects on the uphill battle faced against established medical institutions resistant to change. The update underscores Zhittya’s hypothesis that Parkinson’s and similar diseases stem from vascular dysfunction. Dr. Jacobs’s presentation in Kuwait was met with positive interest, emphasizing the potential of FGF-1 treatment.

Zhittya Genesis Medicine's November 2024 update showcases advances in their FGF-1 treatment research, highlighting its potential to heal vascular dysfunction in the brain. With nearly 200 Parkinson’s patients treated, new protocols delivering 40 times the initial dose show promising results in motor and cognitive improvements. The update discusses using FGF-1 to treat neurodegenerative diseases like dementia, ALS, and autism, and its success in promoting neurogenesis. A key milestone includes upcoming brain scans at Washington University to measure improved blood flow in treated patients. Zhittya remains focused on pre-IPO funding to drive its FDA compliance and clinical trials in 2025.